DCT

1:24-cv-00315

Pfizer Inc v. MSN Laboratories Private Ltd

Log In
Key Events
Amended Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:24-cv-00315, D. Del., 06/05/2024
  • Venue Allegations: Venue for MSN Laboratories is alleged to be proper as it is not a U.S. resident and may be sued in any judicial district. Venue for MSN Pharmaceuticals is alleged to be proper as it is a Delaware corporation.
  • Core Dispute: Plaintiffs allege that Defendants' Abbreviated New Drug Application (ANDA) seeking to market a generic version of Plaintiffs' drug OXBRYTA® (voxelotor) constitutes an act of infringement of two U.S. patents covering crystalline forms and dosing regimens for the active ingredient.
  • Technical Context: The technology relates to voxelotor, a treatment for sickle cell disease, focusing on specific crystalline forms of the drug molecule and methods of its administration to ensure stability and efficacy.
  • Key Procedural History: This is a Hatch-Waxman action initiated after Plaintiffs received a Paragraph IV Notice Letter from Defendants, dated January 24, 2024, regarding ANDA No. 219094. The complaint was filed within the statutory 45-day window, triggering a potential 30-month stay of FDA approval for the generic product. The patents-in-suit are listed in the FDA's "Orange Book" for OXBRYTA®.

Case Timeline

Date Event
2014-02-07 U.S. Patent No. 9,447,071 Priority Date
2015-12-04 U.S. Patent No. 11,020,382 Priority Date
2016-09-20 U.S. Patent No. 9,447,071 Issued
2021-06-01 U.S. Patent No. 11,020,382 Issued
2024-01-24 MSN Paragraph IV Notice Letter Sent
2024-06-05 First Amended Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,447,071 - "Crystalline Polymorphs of the Free Base of 2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde"

  • Patent Identification: U.S. Patent No. 9,447,071, "Crystalline Polymorphs of the Free Base of 2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde," issued September 20, 2016 (Compl. ¶9).

The Invention Explained

  • Problem Addressed: The patent background describes the importance of selecting a stable crystalline form of a therapeutic agent for manufacturing and formulation, noting that salt forms of the active ingredient, voxelotor, were found to be unstable and disproportionate in water (Compl. Ex. A, '071 Patent, col. 2:16-30).
  • The Patented Solution: The invention identifies and characterizes specific stable crystalline ansolvate (solvent-free) forms of the voxelotor free base, designated as Form I, Form II, and Material N ('071 Patent, abstract; '071 Patent, col. 2:39-42). These forms are defined by their unique X-ray powder diffraction (XRPD) patterns, which provide a "fingerprint" for each crystal structure ('071 Patent, FIG. 2).
  • Technical Importance: Identifying stable polymorphs is a critical step in drug development, as it ensures product consistency, stability during storage, and predictable bioavailability for the patient ('071 Patent, col. 1:60-col. 2:14).

Key Claims at a Glance

  • The complaint asserts infringement of "one or more claims," with claim 1 cited as an example (Compl. ¶35; Compl. ¶37).
  • Independent claim 1 requires:
    • A crystalline ansolvate of Compound 1 (voxelotor).
    • Wherein the crystalline ansolvate is characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ) (Compl. ¶37).

U.S. Patent No. 11,020,382 - "Dosing Regimens for 2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde"

  • Patent Identification: U.S. Patent No. 11,020,382, "Dosing Regimens for 2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde," issued June 1, 2021 (Compl. ¶10).

The Invention Explained

  • Problem Addressed: The patent addresses the challenge of treating sickle cell disease with voxelotor, which can require frequent, high-dose administration that may lead to poor patient compliance and high treatment costs (Compl. Ex. B, '382 Patent, col. 2:1-4).
  • The Patented Solution: The invention claims a specific method for treating sickle cell disease by orally administering a once-daily dose of "about 1500 mg" of voxelotor, where the drug is in the specific crystalline ansolvate form (Form II) characterized by particular XRPD peaks ('382 Patent, abstract; '382 Patent, claim 1). This specific regimen is disclosed as being therapeutically effective ('382 Patent, col. 4:1-4).
  • Technical Importance: Establishing an optimized and convenient once-daily dosing regimen improves patient adherence and therapeutic outcomes for chronic conditions like sickle cell disease.

Key Claims at a Glance

  • The complaint asserts infringement of "one or more claims," with claim 1 cited as an example (Compl. ¶59; Compl. ¶62).
  • Independent claim 1 requires:
    • A method for treating sickle cell disease in a human patient by administering Compound 1 (voxelotor).
    • Administering the compound orally in a dose of "about 1500 mg once daily."
    • The Compound 1 is in a crystalline ansolvate form characterized by X-ray powder diffraction peaks (Cu Kα radiation) at 13.37°, 14.37°, 19.95°, and 23.92° 2θ, each peak is ± 0.2° 2θ (Compl. ¶62).

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is the proposed generic voxelotor tablet product for which Defendants MSN Laboratories Private Ltd. and MSN Pharmaceuticals Inc. submitted Abbreviated New Drug Application (ANDA) No. 219094 to the FDA (Compl. ¶13).

Functionality and Market Context

  • The complaint alleges that the "MSN's ANDA Product" is a generic copy of Plaintiffs' OXBRYTA® tablets, which are used for the treatment of sickle cell disease (Compl. ¶11; Compl. ¶15).
  • The ANDA submission relies on the safety and efficacy data of Plaintiffs' approved New Drug Application for OXBRYTA® and purports to establish bioequivalence (Compl. ¶16).
  • By filing the ANDA, Defendants are seeking FDA approval to manufacture and sell their generic voxelotor tablets in the United States before the expiration of the patents-in-suit (Compl. ¶13).

IV. Analysis of Infringement Allegations

9,447,071 Infringement Allegations

The complaint includes a visual of the chemical structure for Compound 1, which is the active ingredient voxelotor (Compl. ¶37).

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A crystalline ansolvate of Compound 1 The complaint alleges that MSN's ANDA Product will contain a crystalline ansolvate form of the active ingredient, Compound 1. ¶38 col. 2:31-33
wherein the crystalline ansolvate is characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95° and 23.92° 2θ (each ±0.2° 2θ). It is alleged that the crystalline ansolvate in MSN's ANDA Product will be characterized by one or more of the specific X-ray powder diffraction peaks recited in the claim. ¶38 col. 4:1-12

11,020,382 Infringement Allegations

The complaint provides a visual representation of Compound 1's chemical structure as part of its infringement allegations for the '382 patent (Compl. ¶62).

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for treating sickle cell disease in a human patient in need thereof comprising administering to the patient Compound 1 The complaint alleges that MSN's ANDA Product, upon approval, will be used in a method for treating sickle cell disease by administering Compound 1 to a patient. ¶63 col. 2:10-12
wherein Compound 1 is administered orally in a dose of about 1500 mg once daily It is alleged that Compound 1 in MSN's ANDA Product will be administered orally at a dose of about 1500 mg once daily, presumably based on the proposed product labeling. ¶63 col. 4:1-2
and Compound 1 is in a crystalline ansolvate form characterized by X-ray powder diffraction peaks (Cu Kα radiation) at 13.37°, 14.37°, 19.95°, and 23.92° 2θ, each peak is ± 0.2° 2θ. The complaint alleges that the Compound 1 in MSN's ANDA Product is in the specific crystalline ansolvate form (Form II) defined by the recited XRPD peaks. ¶63 col. 3:28-33

Identified Points of Contention

  • Evidentiary Question: A central factual dispute will likely concern the physical characterization of MSN's ANDA product. The infringement allegation hinges on whether MSN's product contains a crystalline form of voxelotor that exhibits the specific XRPD peaks recited in the claims. This will be a matter of competing expert analysis of the accused product.
  • Scope Question: For the '382 Patent, the construction of "about 1500 mg" may be a point of contention. The analysis will question what range of dosages is covered by this term and whether MSN's proposed label instructs for a dosage that falls within that scope.

V. Key Claim Terms for Construction

  • The Term: "crystalline ansolvate" (from '071 Patent, claim 1; '382 Patent, claim 1)

  • Context and Importance: This term defines the required physical form of the active ingredient. Its construction is critical because infringement depends on the accused product containing this specific form, as opposed to an amorphous version, a different polymorph, or a solvate (a form containing solvent in its crystal lattice).

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The claims themselves define the "crystalline ansolvate" functionally by its XRPD peaks, which may support an argument that any crystalline form meeting those peak characteristics qualifies, regardless of its preparation method or minor impurities.
    • Evidence for a Narrower Interpretation: The specification extensively discusses specific ansolvate forms, namely Form I, Form II, and Material N ('071 Patent, col. 2:39-42). A party may argue that the term should be limited to these explicitly described embodiments, particularly Form II, which corresponds to the peaks in the asserted claims. The description of Form II as "substantially free" of other forms could also be used to argue for a high-purity requirement ('071 Patent, col. 4:50-53).

  • The Term: "about 1500 mg" (from '382 Patent, claim 1)

  • Context and Importance: This term is central to the claimed dosing regimen. Its interpretation will determine the range of daily dosages that constitute infringement. Practitioners may focus on this term because the commercial viability of a generic could depend on offering a dosage strength outside a narrowly construed range.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specification discusses clinical development with doses "in the range of 500 mg to 1000 mg, or up to 1500 mg" ('382 Patent, col. 1:47-49, as found in related '035 patent). The use of the word "about" itself implies a degree of numerical flexibility that is not strictly limited to 1500 mg.
    • Evidence for a Narrower Interpretation: The patent specifically claims "about 1500 mg," distinguishing it from other doses like "600 mg" and "900 mg" that are also discussed as therapeutic amounts ('382 Patent, col. 1:57-61). This may support an argument that "about" encompasses only minor variations from 1500 mg and does not extend to other numerically distinct dosage strengths.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges both induced and contributory infringement for both patents (Compl. ¶¶36, 41, 61, 66). Inducement of the '382 method patent is based on the allegation that Defendants' proposed product labeling will instruct physicians and patients to administer the generic drug according to the claimed method (Compl. ¶63). Contributory infringement is alleged on the basis that the ANDA product is "especially made or adapted for use in infringing" the patents and is not suitable for a "substantial non-infringing use" (Compl. ¶41; Compl. ¶66).
  • Willful Infringement: Plaintiffs allege that Defendants acted with "full knowledge" of the patents-in-suit and "without a reasonable basis for believing" they would not be liable for infringement (Compl. ¶39; Compl. ¶64). This allegation is based on Defendants' pre-suit knowledge of the patents, as evidenced by their submission of Paragraph IV certifications against the Orange Book-listed patents-in-suit.

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of polymorphic identity: what does the evidence from Defendants' ANDA submission and any subsequent discovery show regarding the crystalline form of voxelotor in the proposed generic product? The case will turn on whether that form exhibits the specific X-ray powder diffraction characteristics required by the asserted claims.
  • A key legal question will be one of claim scope: can the term "about 1500 mg once daily" in the '382 patent be construed to read on the dosage regimen instructed by the proposed labeling for Defendants' generic product? The outcome of this construction will be pivotal to the infringement analysis of the method patent.
  • Finally, an overarching question, typical of ANDA litigation, will be one of patent validity: assuming Plaintiffs can establish infringement, will Defendants be able to demonstrate by clear and convincing evidence that the asserted claims are invalid as obvious or otherwise unpatentable in light of the prior art concerning sickle cell disease treatments and pharmaceutical formulation?